Kymera
lead selective for tumors irrespective of mutations | Kymera
Company
Deck Type
IPO
Sector
Industry
Deck date
August 2020
Slide
32 of 49
Related slides by other companies
RayzeBio
IPO
September 2023
lead clinical indication refractory tumors nets tumors of the tract net and pancreas net have limited als gses | RayzeBio
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights